Symbols / TOVX
TOVX Chart
About
Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorectal cancer; and a Phase 1 clinical study for the treatment of solid tumors. It also develops VCN-11 for treating solid tumors; SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage to prevent overgrowth and infection by pathogenic organisms, such Clostridioides difficile infection and vancomycin resistant Enterococci, and reducing the incidence and severity of acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases. In addition, the company develops clinical stage products, such as SYN-006 to prevent aGVHD and infection by carbapenem resistant enterococci; and SYN-007 for preventing antibiotic associated diarrhea with oral ß-lactam antibiotics. It has collaboration agreements with The University of Texas at Austin, Catalan Institute of Oncology, Fundació Privada Institut d'Investigacio Biomedica de Bellvitge, Saint Joan De Déu, and Massachusetts General Hospital, as well as a clinical trial agreement with Washington University School of Medicine in St. Louis to conduct a Phase 1b/2a clinical trial of SYN-004. Theriva Biologics, Inc. is headquartered in Rockville, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 6.99M |
| Enterprise Value | 1.14M | Income | -26.19M | Sales | — |
| Book/sh | 0.65 | Cash/sh | 0.22 | Dividend Yield | — |
| Payout | 0.00% | Employees | 20 | IPO | — |
| P/E | 0.10 | Forward P/E | -0.26 | PEG | — |
| P/S | — | P/B | 0.30 | P/C | — |
| EV/EBITDA | -0.07 | EV/Sales | — | Quick Ratio | 0.85 |
| Current Ratio | 0.90 | Debt/Eq | 40.99 | LT Debt/Eq | — |
| EPS (ttm) | 2.06 | EPS next Y | -0.75 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 08:00 | ROA | -29.21% |
| ROE | -166.96% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 35.69M |
| Shs Float | 33.03M | Short Float | 21.28% | Short Ratio | 1.83 |
| Short Interest | — | 52W High | 1.60 | 52W Low | 0.17 |
| Beta | 0.57 | Avg Volume | 10.07M | Volume | 4.29M |
| Target Price | — | Recom | Hold | Prev Close | $0.18 |
| Price | $0.20 | Change | 11.94% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.20
Latest analyst target
3. DCF / Fair value
$-2.66
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.20
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-05-08 | down | Maxim Group | Buy → Hold | — |
| 2024-11-13 | main | Maxim Group | Buy → Buy | $6 |
- Trial tests VCN-01 before eye removal in hard-to-treat retinoblastoma - Stock Titan ue, 03 Feb 2026 08
- TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active - Meyka Fri, 20 Feb 2026 12
- Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com Mon, 29 Dec 2025 08
- Theriva Licenses SYN-020, Refocuses on Cancer Pipeline - TipRanks Wed, 18 Feb 2026 13
- Theriva Biologics (TOVX) Stock Surges on Cancer Trial Breakthrough – What’s Next? - TechStock² Fri, 24 Oct 2025 07
- Gut-targeted SYN-020 licensed to treat metabolic and inflammatory disease - Stock Titan Wed, 18 Feb 2026 13
- Theriva Biologics (TOVX) Addresses Unusual Stock Activity - GuruFocus Fri, 24 Oct 2025 07
- Why Is Theriva Biologics Stock Gaining Monday? - Benzinga Mon, 29 Dec 2025 08
- Theriva Biologics Provides Response to Unusual Market Action - Yahoo Finance Fri, 24 Oct 2025 07
- Theriva Biologics Faces Delay in Warrant Approval Meeting - TipRanks hu, 12 Feb 2026 08
- Theriva Biologics (TOVX) Stock Soars 92% on Oncolytic Virus Trial News – Can the Rally Last? - TechStock² Wed, 15 Oct 2025 07
- Theriva Biologics (NYSE American: TOVX) reports cash $15.5M, runway into 2027 - Stock Titan Wed, 12 Nov 2025 08
- TOVX: Theriva Biologics Downgraded by Maxim Group | TOVX Stock N - GuruFocus hu, 08 May 2025 07
- Theriva Biologics files prospectus for up to $4 million at-the-market offering - Investing.com Fri, 24 Oct 2025 07
- $4.0M Gross Proceeds: Theriva Biologics' Warrant Inducement Issues 14.72M New Warrants - Stock Titan hu, 16 Oct 2025 07
Insider Transactions
No recent insider transactions.
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 246.00 | -2.77K | 0.00 |
| TaxRateForCalcs | 0.00 | 0.08 | 0.07 | 0.00 |
| NormalizedEBITDA | -12.37M | -21.30M | -21.45M | -14.19M |
| TotalUnusualItems | -6.92M | 3.00K | -41.00K | |
| TotalUnusualItemsExcludingGoodwill | -6.92M | 3.00K | -41.00K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -25.65M | -18.35M | -19.68M | -14.27M |
| ReconciledDepreciation | 137.00K | 135.00K | 85.00K | 87.00K |
| EBITDA | -19.29M | -21.30M | -21.50M | -14.19M |
| EBIT | -19.43M | -21.43M | -21.58M | -14.27M |
| NetInterestIncome | 697.00K | 1.44M | 512.00K | 6.00K |
| InterestIncome | 697.00K | 1.44M | 512.00K | 6.00K |
| NormalizedIncome | -18.73M | -18.35M | -19.65M | -14.27M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -25.65M | -18.35M | -19.68M | -14.27M |
| TotalExpenses | 19.43M | 21.43M | 21.58M | 14.27M |
| TotalOperatingIncomeAsReported | -26.35M | -21.43M | -21.58M | -14.27M |
| DilutedAverageShares | 1.35M | 644.28K | 613.09K | 487.50K |
| BasicAverageShares | 1.35M | 644.28K | 613.09K | 487.50K |
| DilutedEPS | -19.03 | -28.48 | -32.75 | -47.50 |
| BasicEPS | -19.03 | -28.48 | -32.75 | -47.50 |
| DilutedNIAvailtoComStockholders | -25.65M | -18.35M | -20.02M | -23.19M |
| NetIncomeCommonStockholders | -25.65M | -18.35M | -20.02M | -23.19M |
| OtherunderPreferredStockDividend | 0.00 | 340.00K | 7.40M | |
| PreferredStockDividends | 1.52M | |||
| NetIncome | -25.65M | -18.35M | -19.68M | -14.27M |
| MinorityInterests | 0.00 | 1.00K | ||
| NetIncomeIncludingNoncontrollingInterests | -25.65M | -18.35M | -19.68M | -14.27M |
| NetIncomeContinuousOperations | -25.65M | -18.35M | -19.68M | -14.27M |
| TaxProvision | 0.00 | -1.64M | -1.43M | 0.00 |
| PretaxIncome | -25.65M | -19.99M | -21.11M | -14.27M |
| OtherIncomeExpense | -6.92M | 3.00K | -41.00K | |
| SpecialIncomeCharges | -6.92M | 0.00 | ||
| WriteOff | 1.32M | 0.00 | ||
| ImpairmentOfCapitalAssets | 5.59M | 0.00 | ||
| GainOnSaleOfSecurity | -4.00K | 3.00K | -41.00K | |
| NetNonOperatingInterestIncomeExpense | 697.00K | 1.44M | 512.00K | 6.00K |
| InterestIncomeNonOperating | 697.00K | 1.44M | 512.00K | 6.00K |
| OperatingIncome | -19.43M | -21.43M | -21.58M | -14.27M |
| OperatingExpense | 19.43M | 21.43M | 21.58M | 14.27M |
| ResearchAndDevelopment | 12.03M | 14.31M | 11.72M | 7.80M |
| SellingGeneralAndAdministration | 7.40M | 7.12M | 9.86M | 6.47M |
| GeneralAndAdministrativeExpense | 7.40M | 7.12M | 9.86M | 6.47M |
| OtherGandA | 7.40M | 7.12M | 9.86M | 6.47M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TreasurySharesNumber | 28.81K | 28.81K | 28.80K | 9.00 |
| OrdinarySharesNumber | 2.78M | 685.92K | 604.96K | 528.17K |
| ShareIssued | 2.81M | 714.73K | 633.76K | 528.18K |
| TotalDebt | 1.56M | 2.15M | 1.68M | 1.53M |
| TangibleBookValue | 1.71M | 11.51M | 27.16M | 65.41M |
| InvestedCapital | 19.22M | 37.19M | 52.11M | 65.41M |
| WorkingCapital | 8.70M | 20.66M | 38.46M | 65.30M |
| NetTangibleAssets | 1.71M | 14.24M | 29.89M | 65.41M |
| CapitalLeaseObligations | 1.41M | 1.93M | 1.40M | 1.53M |
| CommonStockEquity | 19.07M | 36.96M | 51.83M | 65.41M |
| PreferredStockEquity | 2.73M | 2.73M | ||
| TotalCapitalization | 19.16M | 39.86M | 54.78M | 65.41M |
| TotalEquityGrossMinorityInterest | 19.07M | 39.70M | 54.56M | 65.41M |
| MinorityInterest | 0.00 | |||
| StockholdersEquity | 19.07M | 39.70M | 54.56M | 65.41M |
| GainsLossesNotAffectingRetainedEarnings | -1.18M | 32.00K | -679.00K | 0.00 |
| OtherEquityAdjustments | -1.18M | 32.00K | -679.00K | |
| TreasuryStock | 288.00K | 288.00K | 288.00K | |
| RetainedEarnings | -334.97M | -309.32M | -290.97M | -271.28M |
| AdditionalPaidInCapital | 355.50M | 346.54M | 343.75M | 336.68M |
| CapitalStock | 3.00K | 2.73M | 2.75M | 13.00K |
| CommonStock | 3.00K | 1.00K | 16.00K | 13.00K |
| PreferredStock | 0.00 | 2.73M | 2.73M | 0.00 |
| TotalLiabilitiesNetMinorityInterest | 16.29M | 15.52M | 17.30M | 4.96M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 8.70M | 8.78M | 10.24M | 1.40M |
| OtherNonCurrentLiabilities | 6.97M | 6.27M | 7.21M | |
| NonCurrentDeferredLiabilities | 762.00K | 906.00K | 1.62M | 0.00 |
| NonCurrentDeferredTaxesLiabilities | 762.00K | 906.00K | 1.62M | 0.00 |
| LongTermDebtAndCapitalLeaseObligation | 965.00K | 1.60M | 1.41M | 1.40M |
| LongTermCapitalLeaseObligation | 873.00K | 1.44M | 1.19M | 1.40M |
| LongTermDebt | 92.00K | 162.00K | 221.00K | |
| CurrentLiabilities | 7.58M | 6.74M | 7.06M | 3.55M |
| OtherCurrentLiabilities | 2.97M | |||
| CurrentDeferredLiabilities | 1.61M | 906.00K | 0.00 | |
| CurrentDeferredTaxesLiabilities | 1.61M | 906.00K | 0.00 | |
| CurrentDebtAndCapitalLeaseObligation | 600.00K | 550.00K | 273.00K | 124.00K |
| CurrentCapitalLeaseObligation | 539.00K | 487.00K | 216.00K | 124.00K |
| CurrentDebt | 61.00K | 63.00K | 57.00K | |
| OtherCurrentBorrowings | 61.00K | 63.00K | 57.00K | |
| PensionandOtherPostRetirementBenefitPlansCurrent | 187.00K | 127.00K | 87.00K | 0.00 |
| PayablesAndAccruedExpenses | 5.18M | 5.16M | 3.73M | 3.43M |
| CurrentAccruedExpenses | 4.33M | 4.38M | 2.81M | 2.91M |
| Payables | 859.00K | 770.00K | 915.00K | 524.00K |
| AccountsPayable | 859.00K | 770.00K | 915.00K | 524.00K |
| TotalAssets | 35.35M | 55.22M | 71.86M | 70.36M |
| TotalNonCurrentAssets | 19.07M | 27.82M | 26.34M | 1.51M |
| OtherNonCurrentAssets | 171.00K | 180.00K | 122.00K | 23.00K |
| NonCurrentPrepaidAssets | 23.00K | 23.00K | ||
| GoodwillAndOtherIntangibleAssets | 17.36M | 25.45M | 24.68M | 0.00 |
| OtherIntangibleAssets | 17.36M | 19.75M | 19.15M | |
| Goodwill | 0.00 | 5.70M | 5.53M | 0.00 |
| NetPPE | 1.54M | 2.18M | 1.54M | 1.48M |
| AccumulatedDepreciation | -935.00K | -1.00M | -865.00K | -831.00K |
| GrossPPE | 2.48M | 3.18M | 2.41M | 2.31M |
| Leases | 94.00K | 94.00K | 94.00K | 94.00K |
| OtherProperties | 1.66M | 2.18M | 1.41M | 1.38M |
| MachineryFurnitureEquipment | 719.00K | 913.00K | 908.00K | 838.00K |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 16.28M | 27.40M | 45.52M | 68.86M |
| PrepaidAssets | 1.35M | 2.29M | 3.50M | 1.53M |
| Receivables | 3.32M | 1.94M | 231.00K | 0.00 |
| OtherReceivables | 144.00K | |||
| TaxesReceivable | 3.32M | 1.94M | 87.00K | 0.00 |
| CashCashEquivalentsAndShortTermInvestments | 11.61M | 23.18M | 41.79M | 67.33M |
| CashAndCashEquivalents | 11.61M | 23.18M | 41.79M | 67.33M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -16.94M | -19.20M | -19.20M | -12.90M |
| RepurchaseOfCapitalStock | 0.00 | -288.00K | 0.00 | |
| RepaymentOfDebt | -67.00K | -75.00K | -1.38M | 0.00 |
| IssuanceOfCapitalStock | 5.56M | 2.22M | 2.73M | 65.96M |
| CapitalExpenditure | -1.00K | -202.00K | -116.00K | -14.00K |
| EndCashPosition | 11.71M | 23.28M | 41.88M | 67.33M |
| BeginningCashPosition | 23.28M | 41.88M | 67.33M | 6.23M |
| EffectOfExchangeRateChanges | -132.00K | -33.00K | -32.00K | 0.00 |
| ChangesInCash | -11.44M | -18.57M | -25.41M | 61.10M |
| FinancingCashFlow | 5.50M | 625.00K | -1.93M | 74.00M |
| CashFlowFromContinuingFinancingActivities | 5.50M | 625.00K | -1.93M | 74.00M |
| NetOtherFinancingCharges | -1.52M | -3.00M | ||
| ProceedsFromStockOptionExercised | 0.00 | 8.04M | ||
| NetPreferredStockIssuance | 0.00 | 2.73M | 0.00 | |
| PreferredStockIssuance | 0.00 | 2.73M | 0.00 | |
| NetCommonStockIssuance | 5.56M | 2.22M | -288.00K | 65.96M |
| CommonStockPayments | 0.00 | -288.00K | 0.00 | |
| CommonStockIssuance | 5.56M | 2.22M | 0.00 | 65.96M |
| NetIssuancePaymentsOfDebt | -67.00K | -75.00K | -1.38M | 0.00 |
| NetLongTermDebtIssuance | -67.00K | -75.00K | -1.38M | 0.00 |
| LongTermDebtPayments | -67.00K | -75.00K | -1.38M | 0.00 |
| InvestingCashFlow | -1.00K | -202.00K | -4.40M | -14.00K |
| CashFlowFromContinuingInvestingActivities | -1.00K | -202.00K | -4.40M | -14.00K |
| NetBusinessPurchaseAndSale | 0.00 | -4.28M | 0.00 | |
| PurchaseOfBusiness | 0.00 | -4.28M | 0.00 | |
| NetPPEPurchaseAndSale | -1.00K | -202.00K | -116.00K | -14.00K |
| PurchaseOfPPE | -1.00K | -202.00K | -116.00K | -14.00K |
| OperatingCashFlow | -16.94M | -19.00M | -19.08M | -12.89M |
| CashFlowFromContinuingOperatingActivities | -16.94M | -19.00M | -19.08M | -12.89M |
| ChangeInWorkingCapital | 726.00K | 2.31M | -806.00K | 709.00K |
| ChangeInOtherWorkingCapital | 333.00K | 110.00K | ||
| ChangeInOtherCurrentLiabilities | -482.00K | -422.00K | -124.00K | -216.00K |
| ChangeInOtherCurrentAssets | 166.00K | |||
| ChangeInPayablesAndAccruedExpense | 295.00K | 1.42M | -319.00K | 751.00K |
| ChangeInAccruedExpense | 172.00K | 1.57M | 66.00K | 1.11M |
| ChangeInPayable | 123.00K | -157.00K | -385.00K | -363.00K |
| ChangeInAccountPayable | 123.00K | -157.00K | -385.00K | -363.00K |
| ChangeInPrepaidAssets | 913.00K | 1.31M | -363.00K | 174.00K |
| OtherNonCashItems | 1.15M | -2.00M | 2.27M | 166.00K |
| StockBasedCompensation | 671.00K | 552.00K | 475.00K | 416.00K |
| AssetImpairmentCharge | 6.92M | 0.00 | ||
| DeferredTax | -888.00K | -1.64M | -1.43M | 0.00 |
| DeferredIncomeTax | -888.00K | -1.64M | -1.43M | 0.00 |
| DepreciationAmortizationDepletion | 137.00K | 135.00K | 85.00K | 87.00K |
| DepreciationAndAmortization | 137.00K | 135.00K | 85.00K | 87.00K |
| Depreciation | 137.00K | 135.00K | 85.00K | 87.00K |
| NetIncomeFromContinuingOperations | -25.65M | -18.35M | -19.68M | -14.27M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for TOVX
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|